Madeline G. Huey

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere et al. · JCI Insight · 2016 · 75 citations · Full text

Fms-like Tyrosine Kinase, Mixed-phenotype Acute Leukemia, Resistance-conferring Flt3 Mutations +17

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Deborah DeRyckere, Alisa B. Lee‐Sherick, Madeline G. Huey et al. · Clinical Cancer Research · 2016 · 71 citations · Full text

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity

Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry et al. · JCI Insight · 2018 · 71 citations · Full text

Hematological Malignancy, Host Mertk, Cancer Immunosurveillance +14

Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae

Peter M. Grace, Khara M. Ramos, Krista M. Rodgers et al. · Neuroscience · 2014 · 65 citations

Inflammation, Toll-like Receptors, Neuroinflammation +14

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology

Chenxiao Da, Dehui� Zhang, Michael A. Stashko et al. · Journal of the American Chemical Society · 2019 · 20 citations · Full text

Drug Target, Large Protein Family, Tumor Biology +16